

# Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

View Online



Clinical Presentation & Management of Diabetes:  
Complications & Cardiovascular Disease

---

1.  
Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. Textbook of Diabetes. (John Wiley & Sons, Incorporated, 2016).
2.  
Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).
3.  
International Textbook of Diabetes Mellitus. (John Wiley & Sons, Incorporated, 2015).
4.  
Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE.
5.  
Type 2 diabetes in adults: management | Guidance and guidelines | NICE.
6.  
Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. The Lancet (2017)  
doi:10.1016/S0140-6736(17)30058-2.

7.

Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. *The Lancet* **383**, 69–82 (2014).

8.

Matheus, A. S. de M. et al. Impact of Diabetes on Cardiovascular Disease: An Update. *International Journal of Hypertension* **2013**, 1–15 (2013).

9.

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey.

10.

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey.

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>.

11.

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. W. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine* **359**, 1577–1589 (2008).

12.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *The Lancet* **352**, 854–865 (1998).

13.

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine* **358**, 2545–2559 (2008).

14.

Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* **52**, 2288–2298 (2009).

15.

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. *New England Journal of Medicine* **364**, 818–828 (2011).

16.

Miller, M. E. et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ* **340**, b5444–b5444 (2010).

17.

Duckworth, W. et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *New England Journal of Medicine* **360**, 129–139 (2009).

18.

Hayward, R. A. et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **372**, 2197–2206 (2015).

19.

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* **358**, 2560–2572 (2008).

20.

Wong, M. G. et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care* **39**, 694–700 (2016).

21.

Giorgino, F., Home, P. D. & Tuomilehto, J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care* **39**, S187–S195 (2016).

22.

Gæde, P., Lund-Andersen, H., Parving, H.-H. & Pedersen, O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine* **358**, 580–591 (2008).

23.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine* **329**, 977–986 (1993).

24.

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. *New England Journal of Medicine* **353**, 2643–2653 (2005).

25.

Orchard, T. J. et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. *JAMA* **313**, (2015).

26.

Gæde, P. et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia* **59**, 2298–2307 (2016).

27.

Bianchi, C., Miccoli, R. & Del Prato, S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports* **13**, 403–410 (2013).

28.

Zinman, B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine* **373**, 2117–2128 (2015).

29.

Marso, S. P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **375**, 311–322 (2016).

30.

Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ* **343**, d4169–d4169 (2011).

31.

Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *The Lancet* **373**, 1765–1772 (2009).

32.

Sultan, A. et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine* (2017) doi:10.1111/dme.13364.

33.

Rawshani, A. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* **376**, 1407–1418 (2017).

34.

Sultan, A. et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine* (2017) doi:10.1111/dme.13364.

35.

Soliman, E. Z. et al. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care* **40**, 793–799 (2017).

36.

Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care* **40**, 809.3-809 (2017).

37.

Mayer-Davis, E. J. et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *New England Journal of Medicine* **376**, 1419–1429 (2017).

38.

Rawshani, A. et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* **376**, 1407–1418 (2017).

39.

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* **377**, 300–301 (2017).

40.

Older antidiabetic drugs | The British Journal of Cardiology.  
<https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>.

41.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S22138587183>

00354.

42.

Holman, R. R. et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **377**, 1228–1239 (2017).

43.

Pickering, R. J. et al. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clinical & Translational Immunology* **7**, (2018).

44.

Microvascular Complications and Foot Care. *Diabetes Care* **40**, S88–S98 (2017).

45.

Valencia, W. M. & Florez, H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. *BMJ* (2017) doi:10.1136/bmj.i6505.

46.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet* **375**, 2215–2222 (2010).

47.

The changing face of diabetes complications - ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>.

48.

Wong, M. G. et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care* **39**, 694–700 (2016).

49.

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. *New England Journal of Medicine* **364**, 829–841 (2011).

50.

Wannamethee, S. G., Shaper, A. G., Whincup, P. H., Lennon, L. & Sattar, N. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel risk factors. *Archives of Internal Medicine* **171**, (2011).

51.

Yudkin, J. S., Richter, B. & Gale, E. A. Intensified glucose control in type 2 diabetes—whose agenda? *The Lancet* **377**, 1220–1222 (2011).

52.

Zhang, C.-Y. et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. *Annals of Medicine* **42**, 305–315 (2010).

53.

Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *European Heart Journal* **36**, 2288–2296 (2015).

54.

Fox, C. S. et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care* **38**, 1777–1803 (2015).

55.



Bianchi, C., Miccoli, R. & Del Prato, S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports* **13**, 403–410 (2013).

56.

Khunti, K. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care* **38**, 316–322 (2015).

57.

Hayward, R. A. et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **372**, 2197–2206 (2015).

58.

Cefalu, W. T., Rosenstock, J., LeRoith, D., Blonde, L. & Riddle, M. C. Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care* **39**, 664–667 (2016).

59.

Black, J. A. et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. *British Journal of General Practice* **64**, e208–e216 (2014).

60.

Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia* **52**, 2288–2298 (2009).

61.

Zoungas, S. et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *The Lancet Diabetes & Endocrinology* **5**, 431–437 (2017).

62.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.

63.

Saha, S. A. & Arora, R. R. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. *International Journal of Cardiology* **141**, 157–166 (2010).

64.

Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? *Clinical Diabetes* **26**, (2008).

65.

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine* **362**, 1563–1574 (2010).

66.

Filippatos, T., Tsimihodimos, V., Pappa, E. & Elisaf, M. Pathophysiology of diabetic dyslipidaemia. *Current Vascular Pharmacology* **15**, 1–1 (2017).

67.

Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Atherosclerosis* **252**, 207–274 (2016).

68.

White, J. et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology* **1**, (2016).

69.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey.  
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036>.

70.

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. <http://www.nice.org.uk/guidance/cg127>.

71.

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine **362**, 1575–1585 (2010).

72.

Ferrannini, E. & Cushman, W. C. Diabetes and hypertension: the bad companions. The Lancet **380**, 601–610 (2012).

73.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal **317**, (1998).

74.

Whelton, P. K. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine **165**, (2005).

75.

Barzilay, J. I. et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes **5**, 153–162 (2012).

76.

Lindholm, L. H. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *The Lancet* **359**, 1004–1010 (2002).

77.

Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet* **366**, 895–906 (2005).

78.

Weber, M. A. et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *Journal of the American College of Cardiology* **56**, 77–85 (2010).

79.

Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *The Lancet* **369**, 201–207 (2007).

80.

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine* **362**, 1575–1585 (2010).

81.

Schrier, R. W., Estacio, R. O. & Jeffers, B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. *Diabetologia* **39**, 1646–1654 (1996).

82.

Bangalore, S., Kumar, S., Lobach, I. & Messerli, F. H. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. *Circulation* **123**, 2799–2810 (2011).

83.

Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. *Archives of Internal Medicine* **165**, (2005).

84.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey.  
<https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>.

85.

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>.

86.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>.

87.

Solomon, S. D. et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* **40**, 412–418 (2017).

88.

Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. *The Lancet* **376**, 124–136 (2010).

89.

Adamsson Eryd, S. et al. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. *Diabetic Medicine* **34**, 411–418 (2017).

90.

Liew, G., Mitchell, P. & Wong, T. Y. Systemic management of diabetic retinopathy. *BMJ* **338**, b441–b441 (2009).

91.

Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* (2017) doi:10.1136/bjophthalmol-2016-310063.

92.

Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* (2017) doi:10.1136/bjophthalmol-2016-310063.

93.

Romero-Aroca, P. et al. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology* (2017) doi:10.1136/bjophthalmol-2016-310063.

94.

Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care* (2017) doi:10.2337/dc17-er06e.

95.

Solomon, S. D. et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care* (2017)  
doi:10.2337/dc17-er06e.

96.

Rosenberg, J. B. & Tsui, I. Screening for Diabetic Retinopathy. *New England Journal of Medicine* **376**, 1587–1588 (2017).

97.

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. *New England Journal of Medicine* **376**, 1507–1516 (2017).

98.

Moreton, R. B. R., Stratton, I. M., Chave, S. J., Lipinski, H. & Scanlon, P. H. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabetic Medicine* **34**, 993–999 (2017).

99.

Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clinical Pharmacology : Advances and Applications* **8**, (2016).

100.

Navaneethan, S. D. et al. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *American Journal of Kidney Diseases* (2017)  
doi:10.1053/j.ajkd.2016.11.018.

101.

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey.

102.

Webb, D. R. et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. *Diabetes/Metabolism Research and Reviews* (2016)  
doi:10.1002/dmrr.2877.

103.

Çakici, N., Fakkal, T. M., van Neck, J. W., Verhagen, A. P. & Coert, J. H. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine* **33**, 1466–1476 (2016).

104.

Koye, D. N. et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine* (2017)  
doi:10.1111/dme.13324.

105.

Johal, S. et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabetic Medicine* (2017)  
doi:10.1111/dme.13383.

106.

Clokie, M. et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. *Diabetic Medicine* **34**, 305–315 (2017).

107.

Game, F. Classification of diabetic foot ulcers. *Diabetes/Metabolism Research and Reviews* **32**, 186–194 (2016).

108.

Jhamb, S., Vangaveti, V. N. & Malabu, U. H. Genetic and molecular basis of diabetic foot ulcers: Clinical review. *Journal of Tissue Viability* **25**, 229–236 (2016).



109.

Boulton, A. J., Jeffcoate, W. J., Jones, T. L. & Ulbrecht, J. S. International collaborative research on Charcot's disease - 2009. *The Lancet* **373**, 105–106 (2009).

110.

Yavuz, M. et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. *Diabetes Care* **40**, e14–e15 (2017).

111.

P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. *The British Journal of Radiology* **88**, (2015).

112.

Diabetic foot problems: prevention and management | Guidance and guidelines | NICE.

113.

Holt, R. I. G. Understanding of the causes and management of diabetic foot disease. *Diabetic Medicine* **34**, 303–304 (2017).

114.

Jin, D., Xu, Y., Geng, D. & Yan, T. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice* **89**, 10–15 (2010).

115.

Çakici, N., Fakkal, T. M., van Neck, J. W., Verhagen, A. P. & Coert, J. H. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine* **33**, 1466–1476 (2016).

116.

Foresta, C., Ferlin, A., Lenzi, A. & Montorsi, P. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. *Andrology* (2017) doi:10.1111/andr.12342.

117.

Azmi, S. et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia* (2017) doi:10.1007/s00125-017-4245-z.

118.

Andersson, D. P. et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. *Heart* (2017) doi:10.1136/heartjnl-2016-310746.

119.

Omland, T., Randby, A., Hrubos-Strøm, H., Røsjø, H. & Einvik, G. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. *The American Journal of Cardiology* **118**, 1821–1825 (2016).

120.

Braffett, B. H., Wessells, H. & Sarma, A. V. Urogenital Autonomic Dysfunction in Diabetes. *Current Diabetes Reports* **16**, (2016).

121.

Hotaling, J. M. et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care* **39**, 1587–1593 (2016).

122.

Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over

Time and Drug and Non-Drug Correlated Factors. PLoS ONE **11**, (2016).

123.

Santi, D. et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. *European Journal of Endocrinology* **174**, 513-522 (2016).

124.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.

125.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.

126.

Malavige, L. S., Wijesekara, P., Ranasinghe, P. & Levy, J. C. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. *European Journal of Medical Research* **20**, (2015).

127.

Hotaling, J. M. et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care* **39**, 1587-1593 (2016).

128.

Dhatariya, K. K. & Vellanki, P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Current Diabetes Reports* **17**, (2017).

129.

Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime.

130.

Dhatariya, K. et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabetic Medicine* **29**, 420–433 (2012).

131.

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey.

<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>.

132.

Scott, A. R. Management of hyperosmolar hyperglycaemic state in adults with diabetes. *Diabetic Medicine* **32**, 714–724 (2015).

133.

Ian Blumer, MD, FRCPC<sup>1, 2</sup>, Maureen Clement, MD, CCFP<sup>3</sup>, . Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. *Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges*.

134.

Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. *PLoS ONE* **10**, (2015).

135.

Khunti, K. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality

in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care* **38**, 316–322 (2015).

136.

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care* **38**, 1583–1591 (2015).

137.

Zaccardi, F. et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. *Diabetologia* (2017) doi:10.1007/s00125-017-4235-1.

138.

Zaccardi, F. et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. *Diabetes, Obesity and Metabolism* (2017) doi:10.1111/dom.12941.

139.

Umpierrez, G. & Korytkowski, M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology* **12**, 222–232 (2016).

140.

Umpierrez, G. & Korytkowski, M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology* **12**, 222–232 (2016).

141.

Micha, R. et al. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA* **317**, (2017).

142.

Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M. & Davies, M. J. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care* **36**, 3411–3417 (2013).

143.

Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L. & Khunti, K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology* **14**, (2015).

144.

Nicolucci, A. & Standl, E. Antiplatelet Therapy for Every Diabetic Person? *Diabetes Care* **34**, S150–S154 (2011).

145.

Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J. & Khunti, K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. *Diabetic Medicine* **33**, 280–289 (2016).

146.

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check.  
[http://www.healthcheck.nhs.uk/news/the\\_handbook\\_for\\_vascular\\_risk\\_assessment\\_risk\\_reduction\\_and\\_risk\\_management/](http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/).

147.

Kunutsor, S. K., Seidu, S. & Khunti, K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. *Diabetic Medicine* **34**, 316–327 (2017).

148.

Fisher, L., Gonzalez, J. S. & Polonsky, W. H. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic Medicine* **31**, 764–772 (2014).

149.

Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA* **317**, 825–835.

150.

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey.

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>.

151.

Dwamena, F. et al. Interventions for providers to promote a patient-centred approach in clinical consultations. in *Cochrane Database of Systematic Reviews* (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD003267.pub2.

152.

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey.

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862>.

153.

Denig, P., Schuling, J., Haaijer-Ruskamp, F. & Voorham, J. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. *BMJ* **349**, g5651–g5651 (2014).

154.

Abdul-Ghani, M. et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care* **40**, 813–820 (2017).

155.

Kaul, S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. *Diabetes Care* **40**, 821–831 (2017).

156.

Ritholz, M. D., MacNeil, T. & Weinger, K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine* (2017)  
doi:10.1111/dme.13419.

157.

Ritholz, M. D., MacNeil, T. & Weinger, K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine* **34**, 1447–1455 (2017).

158.

Textbook of diabetes. (Wiley Blackwell, 2017).

159.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.